FibroBiologics Inc. Commo...

1.22
-0.07 (-5.43%)
At close: Apr 25, 2025, 3:59 PM
1.22
0.00%
After-hours: Apr 25, 2025, 04:05 PM EDT
-5.43%
Bid 1.15
Market Cap 46.04M
Revenue (ttm) n/a
Net Income (ttm) -11.16M
EPS (ttm) -0.34
PE Ratio (ttm) -3.59
Forward PE -2.66
Analyst Buy
Ask 1.25
Volume 167,369
Avg. Volume (20D) 313,306
Open 1.29
Previous Close 1.29
Day's Range 1.16 - 1.28
52-Week Range 0.76 - 13.59
Beta 0.18

About FBLG

FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the tr...

Industry Biotechnology
Sector Healthcare
IPO Date Feb 1, 2024
Employees 13
Stock Exchange NASDAQ
Ticker Symbol FBLG
Full Company Profile

Analyst Forecast

According to 5 analyst ratings, the average rating for FBLG stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 883.61% from the latest price.

Stock Forecasts
4 months ago
-0.87%
FibroBiologics shares are trading higher after Rod... Unlock content with Pro Subscription
6 months ago
+17.82%
FibreBiologics shares are trading higher after the company announced it issued a European patent for fibroblast delivery of tumor inhibitory agents.